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Oxidative stress occurs because of an imbalance between
production of reactive oxygen species and the cell’s capacity
to neutralize them through its intrinsic antioxidant defences.
Key among these is the thioredoxin-peroxiredoxin system
which is an important reducer of oxidative stressors such as
peroxides (Winyard et al. 2005). The thioredoxin system
protects against H2O2-induced apoptosis, and its inhibition
promotes oxidative stress and cell death (Yoshida et al.
2005). The thioredoxin-peroxiredoxin system detoxiﬁes
peroxides by transferring reducing equivalents from NADPH
to peroxides via thioredoxin reductase, thioredoxin and
ﬁnally peroxiredoxins (Prxs). Prxs are a ubiquitous family of
peroxidases with cytoprotective and antioxidative effects
(Immenschuh and Baumgart-Vogt 2005). The 2-Cys Prxs is
the predominant Prx subfamily, comprising Prx I-IV (Wood
et al. 2003) and are implicated in protecting neuronal cells
from Ab toxicity (Yao et al. 2007), excitotoxicity (Hattori
et al. 2003), oxygen-glucose deprivation (Boulos et al.
2007), peroxide (Sanchez-Font et al. 2003; Fang et al.
2007), and MPP+ toxicity (Qu et al. 2007).
These Prxs contain a peroxidatic cysteine residue, oxidized
by peroxides to cysteine sulfenic acid, which then forms a
disulﬁde bond with the resolving cysteine, which is in turn
reduced by thioredoxin (Wood et al. 2003). Sometimes, Prx-
sulfenic acid is further oxidized by peroxide to sulﬁnic
(-SO2H) or sulfonic (-SO3H) acid, causing inactivation of
peroxidase activity (Rhee et al. 2007). Prx-SO2/3H is not a
substrate for the resolving cysteine and cannot be reduced by
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Abstract
Peroxiredoxins are an important family of cysteine-based
antioxidant enzymes that exert a neuroprotective effect in
several models of neurodegeneration. However, under oxi-
dative stress they are vulnerable to inactivation through
hyperoxidation of their active site cysteine residues. We show
that in cortical neurons, the chemopreventive inducer 3H-1,2-
dithiole-3-thione (D3T), that activates the transcription factor
Nuclear factor erythroid 2-related factor (Nrf2), inhibits the
formation of inactivated, hyperoxidized peroxiredoxins fol-
lowing oxidative trauma, and protects neurons against oxi-
dative stress. In both neurons and glia, Nrf2 expression and
treatment with chemopreventive Nrf2 activators, including
D3T and sulforaphane, up-regulates sulfiredoxin, an enzyme
responsible for reducing hyperoxidized peroxiredoxins.
Induction of sulfiredoxin expression is mediated by Nrf2, act-
ing via a cis-acting antioxidant response element (ARE) in its
promoter. The ARE element in Srxn1 contains an embedded
activator protein-1 (AP-1) site which directs induction of Srxn1
by synaptic activity. Thus, raising Nrf2 activity in neurons
prevents peroxiredoxin hyperoxidation and induces a new
member of the ARE-gene family, whose enzymatic function of
reducing hyperoxidized peroxiredoxins may contribute to the
neuroprotective effects of Nrf2 activators.
Keywords: chemoprevention, neurodegeneration, neuropro-
tection, oxidative stress, phase II enzymes, thioredoxin.
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thioredoxin. Hyperoxidation takes place when there is not
enough reduced Prx to deal with peroxides present, and is
associated with oxidative neuronal death in vitro, and also
ischemic brain damage in vivo (Papadia et al. 2008).
Previously, hyperoxidation of Prx was thought to be
irreversible. However, more recently it has been found that
Prx-SO2H can be reduced back to the catalytically active
thiol form in eukaryotic cells by the ATP-dependent
reductase, sulﬁredoxin (Biteau et al. 2003; Rhee et al.
2007; Jonsson et al. 2008). The activity of sulﬁredoxin
restores inactive Prxs back to the thioredoxin cycle and
prevents permanent oxidative inactivation of Prxs by strong
oxidative insults. Over-expression of sulﬁredoxin has been
shown to prevent Prx hyperoxidation in response to an
oxidative insult (Woo et al. 2005). Conversely, knockdown
of sulﬁredoxin prevents reduction of Prx-SO2H following a
transient oxidative insult (Chang et al. 2004).
One known defence against oxidative insults is the
induction of a group of genes encoding antioxidative and
drug-metabolizing enzymes (also known as Phase II
enzymes). These genes are induced by a variety of small
thiol-active molecules including the potent chemopreventive
agent 3H-1,2-dithiole-3-thione (D3T), as well as dietary
phytochemicals such as Sulforaphane (Nguyen et al. 2004).
Mild oxidative stress also induces these genes (Giudice and
Montella 2006). Transcriptional regulation of this group of
genes is mediated by a cis-acting promoter element termed
the antioxidant response element (ARE), which recruits the
transcription factor Nuclear factor erythroid 2-related factor
(Nrf2) as a heterodimer with small Maf proteins (Zhang
2006). Nrf2 levels are constitutively low because of being
targeted for degradation by Keap1. Under conditions of
oxidative stress, Nrf2 degradation is slowed and Nrf2
accumulates in the nucleus and activates ARE-containing
genes, with a net antioxidative effect (Nguyen et al. 2004).
Small molecule activators of Nrf2 also act by interfering
with Keap1-mediated degradation. Activation of Nrf2 and
induction of ARE-driven defences is implicated in protect-
ing against a variety of diseases in many organs and tissues,
including autoimmune diseases, cancer, cardiovascular
disease, neurodegenerative disease and ischemia (Lee et al.
2005; Shih et al. 2005; Giudice and Montella 2006; Zhang
2006). The ability of Nrf2 to exert a cytoprotective effect in
neural cells has mainly been studied in the context of glia.
In a mixed culture of neurons and glial cells, Nrf2
expression in glial cells can confer protection on a large
number of normal non-overexpressing neurons (Shih et al.
2003; Kraft et al. 2004).
Here we ﬁnd that oxidant-induced neuronal apoptosis can
be prevented by expression of Nrf2 speciﬁcally in neurons,
and also by the Nrf2 activator D3T. Furthermore, D3T
strongly impairs oxidant-induced peroxiredoxin hyperoxida-
tion in neurons. D3T induces expression of the enzyme
responsible for reducing hyperoxidized peroxiredoxins, sul-
ﬁredoxin. We ﬁnd that this induction is mediated at the
transcriptional level and that sulﬁredoxin is a new member of
the Nrf2/ARE regulated gene family. Given its function, it
may form part of the cytoprotective gene battery, the
transcription of which is promoted by chemopreventive
agents.
Materials and methods
Tissue culture and the induction of oxidative stress
Cortical rat neurons were cultured as described (Hardingham et al.
2002) from E21 rats except that growth medium contained B27
(Invitrogen, Carlsbad, CA, USA). A single dose of anti-mitotic
agent (AraC, 4.8 lM) was added to the cultures at days in vitro
(DIV) 4 to minimize glial numbers. Experiments were carried out
after being cultured for 8–10 days during which cortical neurons
develop a network of processes, express functional NMDA-type and
a-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate-type
glutamate receptors, and form synaptic contacts. Experiments were
performed after transferring neurons at DIV8 into deﬁned medium
lacking trophic support ‘TMo’ (Papadia et al. 2005): this is
composed of 10% MEM (Invitrogen) and 90% Salt-Glucose-
Glycine medium (SGG: 114 mM NaCl, 0.219% NaHCO3,
5.292 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES,
1 mM Glycine, 30 mM Glucose, 0.5 mM sodium pyruvate, 0.1%
Phenol Red; osmolarity 325 mosm/L, hereafter TMo). D3T (10–
25 lM) was applied to neurons 16 h prior to the application of an
oxidative insult in the form of H2O2 (100 lM, stabilized solution:
Sigma, St Louis, MO, USA). Neurons were ﬁxed after a further 24 h
and subjected to 4,6-diamino-2-phenylindole (DAPI) staining and
cell death quantiﬁed by counting (blind) the number of apoptotic
nuclei as a percentage of the total. Approximately 1500 cells were
counted per treatment, across four independent experiments.
Morphologically, peroxide-treated neurons show typical signs of
apoptotic-like cell death (shrunken cell body and large round
chromatin clumps).
Cultures of cortical glial cells were obtained by plating mixed
neuronal/glial cultures at low density in 10% fetal bovine serum/
Dulbecco’s modiﬁed Eagle’s medium (no anti-mitotic). After 6 days
the small number of neurons that remained were killed by 1 mM
NMDA overnight. This procedure leaves > 99% Glial ﬁbrillary
acidic protein (GFAP) positive glial cells. HEK293 cells were
maintained in 10% FBS/Dulbecco’s modiﬁed Eagle’s medium and
passaged 1 : 5 every 4 days.
Transfection and following the fate of transfected cells
All transfections on all cell types were performed using Lipofec-
tamine 2000 (Invitrogen). Neurons and glial cells were transfected at
DIV8 in TMo (see above). Transfection efﬁciency was approxi-
mately 5% for neuronal cultures. It was found that more than 99% of
enhanced green ﬂuorescent protein (eGFP)-expressing transfected
neurons were neuronal nuclear antigen (NeuN)-positive, and < 1%
were GFAP positive (see results) conﬁrming their neuronal identity.
For monitoring the fate of Nrf2-expressing neurons, peGFP was
used to track the fate of transfected neurons expressing the plasmid
of interest (Nrf2 vs. globin control). To ensure that green ﬂuorescent
protein (GFP)-positive neurons were also expressing the plasmid of
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interest, a favorable ratio was used (peGFP: plasmid of interest,
1 : 2). Coexpression at this ratio was conﬁrmed in the case of a
plasmid encoding red ﬂuorescent protein (Papadia et al. 2008).
Pictures of GFP-expressing neurons were taken using a Leica
AF6000 LX imaging system (Leica Microsystems, Wetzlar,
Germany), with a DFC350 FX digital camera. Neurons were then
treated with 100 lM H2O2 and images of the same cells were taken
24 h after H2O2 exposure. Cell death was assessed by counting the
number of surviving GFP-positive neurons pre- and post-exposure
to H2O2. In the vast majority of cases, death was easily spotted as an
absence of a healthy GFP-expressing cell where one once was. In
place of the cell, there was in most cases (> 90%) evidence of death
in the form of fragmented neurites, ﬂuorescent cell debris, and an
apoptotic nucleus. This conﬁrmed that the cells were genuinely
dying as opposed to more unlikely scenario such as peroxide-
induced quenching of eGFP ﬂuorescence in a sub-population of
neurons. This is also underlined by the fact that death measured by
this technique is blocked by caspase inhibitors (Papadia et al. 2008).
For each plasmid/condition, the fate of approximately 150 neurons
was monitored over three independent experiments.
Plasmids and reporter assays
Srxn1-Luc (Papadia et al. 2008) was subjected to site-directed
mutagenesis of its ARE with the QuikChange II XL site-
directed mutagenesis kit (Stratagene), using the oligonucleotide 5¢-
ACCTGCAAACTCACCCTGGGCCCGCGACCCGACGCGTC-3¢
and its reverse-complementary sequence. The mutation was veriﬁed
by sequencing. ARE-Luc (Numazawa et al. 2003), pcDNA3.1/
V5HisBmNrf2 and pcDNA3.1/V5HisCmKeap1 (McMahon et al.
2003) and pEF-Nrf2 (Kotkow and Orkin 1995) have been described
previously. Fireﬂy luciferase-based reporter gene constructs (Srxn1-
Luc and its ARE mutated variant were transfected along with a
renilla expression vector (pTK-RL), and also, where relevant, other
expression vectors. Luciferase assays were performed 30 h post-
transfection using the Dual Glo assay kit (Promega, Madison, WI,
USA) with Fireﬂy luciferase-based reporter gene activity normalized
to the Renilla control (pTK-RL plasmid) in all cases.
Immunocytochemistry, western blotting and antibodies
Immunoﬂuorescence was performed as described (Mckenzie et al.
2005). Antibodies (Sulﬁredoxin-S17, 1 : 500, Santa Cruz Bio-
technology, Santa Cruz, CA, USA; NeuN, 1 : 15 Chemicon,
Temecula, CA, USA; GFAP, 1 : 1000, Sigma) were incubated
with ﬁxed cells overnight and visualized using biotinylated
secondary antibody/cy3-conjugated streptavidin. Nuclei were
counter-stained with DAPI. Pictures were taken on a Leica
AF6000 LX imaging system, with a DFC350 FX digital camera.
For western blotting, total cell lysates were boiled at 100C for
5 min in 1.5· sample buffer (1.5 M Tris pH 6.8; Glycerol 15%;
sodium dodecyl sulfate 3%; b-mercaptoethanol 7.5%; bromophe-
nol blue 0.0375%). Gel electrophoresis and western blotting were
performed using Xcell Surelock system (Invitrogen) using pre-cast
gradient gels (4–20%) according to the manufacturer’s instruc-
tions. The gels were blotted onto polyvinylidene diﬂuoride
membranes, which were then blocked for 1 h at 20C with 5%
(w/v) non-fat dried milk in Tris-buffered saline with 0.1% Tween
20. The membranes were then incubated at 4C overnight with
the primary antibodies diluted in blocking solution: 2-Cys Prx
(1 : 500, Abcam, Cambridge, UK), Prx-SO2/3H (1 : 1000, Ab-
cam), Sulﬁredoxin (P16, 1 : 250, Santa Cruz), b-tubulin isotype
III (1 : 125 000, Sigma). For visualisation of western blots,
horseradish peroxidase-based secondary antibodies were used
followed by chemiluminescent detection on Kodak X-Omat ﬁlm.
Western blots were analysed by digitally scanning the blots,
followed by densitometric analysis (ImageJ, National Institutes of
Health, Bethesda, MD, USA). All analyses involved normalizing
to a loading control (b-tubulin or Prx).
RNA isolation and qPCR
RNA was isolated using the Qiagen RNeasy kit (Qiagen, Valencia,
CA, USA) (including DNAse treatment) following disruption of cells
(QiaShredder column). cDNA was synthesized from 1–3 lg RNA
using the Stratascript QPCR cDNA Synthesis kit. Dilutions of this
cDNA were used for real-time PCR [cDNA equivalent to 6 ng of
initial RNA per reaction for Srxn1; 3 ng equivalent for Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH)]. qPCR was performed
in anMx3000P QPCR System (Stratagene, La Jolla, CA, USA) using
Brilliant SYBR Green QPCR Master Mix. No-template and no-RT
negative controls were included. Primers used: Srxn1–F: 5¢-GAC-
GTCCTCTGGATCAAAG-3¢ 200 nM, -R: 5¢-GCAGGAATGGTCT-
CTCTCTG-3¢ 200 nM; GAPDH-F: 5¢-GGGTGTGAACCACGA
GAAAT-3¢ 200 nM, -R: 5¢-CCTTCCACAATGCCAAAGTT-3¢
100 nM. 18s rRNA-F: 5¢-GTGGAGCGATTTGTCTGGTT-3¢, -R:
5¢-CAAGCTTATGACCCGCACTT-3¢. Sesn2 F: 5¢-GGATTATACC-
TGGGAAGACC-3¢ 200 nM, -R: 5¢-CGCAGTGGATGTAGTTCC-
3¢ 200 nM. Hmox1 F: 5¢-AGCACAGGGTGACAGAAGAG-3¢
200 nM, -R: 5¢-GGAGCGGTGTCTGGGATG-3¢. The data were
analysed using theMxProQPCR software (Stratagene). Expression of
the Srxn1 was normalized to GAPDH.
Results
Neuronal Nrf2 expression, and the Nrf2 activator D3T,
prevent oxidative neuronal death
Nuclear factor erythroid 2-related factor (Nrf2) over-expres-
sion in glial cells can confer protection on a large number of
normal non-overexpressing neurons (Shih et al. 2003; Kraft
et al. 2004). It is not clear whether Nrf2 can act solely in
neurons to confer neuroprotection against oxidative insults.
We analyzed the neuroprotective effect of boosting Nrf2
activity speciﬁcally in neurons, using a neuron-speciﬁc
transfection protocol previously employed (Papadia et al.
2008) and brieﬂy described below. Cortical ‘neuronal’
cultures naturally contain a small percentage of glial cells
(5–10%). Transfection of these cultures results in tiny
numbers of transfected glial cells, fewer than the 5–10%
expected if both cell types were equally amenable to
transfection (Papadia et al. 2008). To quantify this, mixed
cultures were transfected with eGFP and subjected to NeuN
immunoﬂuorescence. Of 189 eGFP-expressing cells, 186
were NeuN-positive. We then transfected cultures again with
eGFP but this time stained for GFAP. Of 271 eGFP-
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expressing cells, 0 (zero) were GFAP-positive (see example
pictures in Fig. 1a). Thus, nearly all transfected cells in
neuronal cultures are neurons, potentially due the fact that
quiescent (AraC-treated) glial cells are not amenable to
transfection (NB. Non-quiescent glial cells are amenable to
transfection-see below).
We transfected the Nrf2-expressing constructs into neu-
rons, along with an eGFP co-transfection marker to enable us
to monitor the fate of the neurons [a technique previously
described (Papadia et al. 2008)]. Pictures of eGFP-express-
ing neurons were taken 24 h post-transfection, after which
neurons were treated with an oxidative insult (100 lM
H2O2). After a further 24 h pictures of the same cells were
taken, before the cultures were ﬁxed and nuclear integrity
assessed by DAPI staining. By monitoring the neurons
before and after H2O2 treatment, we found that neurons
expressing Nrf2 were completely resistant to cell death
following H2O2 treatment (100 lM, Fig. 1b, see example
pictures in Fig. 1d). We also studied the fate of neurons
within a 150 lm radius of Nrf2-transfected neurons and
found that susceptibility of neurons to death by H2O2
treatment was not changed by being in close proximity to a
Nrf2-expressing neuron (Fig. 1c), in contrast to the reported
non-autonomous effects of Nrf2-expressing glial cells (Shih
et al. 2003).
We next investigated the inﬂuence of known activators of
Nrf2 activity on cortical neuronal vulnerability to an
oxidative insult (H2O2) in vitro. We tested D3T, sulforaphane
and tert-butylhydroquinone (tBHQ). The drugs were applied
at a wide range of concentrations for 16 h prior to the
application of H2O2 (for further 24 h). The protection that
was achieved by these inducing agents varied: D3T conferred
signiﬁcant and strong neuroprotection (Fig. 1e), whereas
tBHQ and sulforaphane were signiﬁcantly less potent at the
range of doses tested (data not shown). Further studies using
D3T revealed that increased neuroprotection at a lower dose
(10 lM) could be achieved by applying a second identical
dose of the compound immediately prior to the oxidative
insult (Fig. 1e).
D3T prevents the thioredoxin-peroxiredoxin system from
becoming overwhelmed by oxidative stress
The existence of hyperoxidized Prx-SO2/3H in neurons
indicates an overwhelmed thioredoxin-peroxiredoxin sys-
tem, and its formation is associated with oxidative neuronal
death (Papadia et al. 2008). We therefore investigated
whether the neuroprotective effects of D3T were associated
with changes in Prx-SO2/3H levels. Western analysis using a
Prx-SO2/3H-speciﬁc antibody revealed that H2O2 caused Prx
hyperoxidation in vehicle (control)-treated neurons, while
D3T-treated neurons displayed far less hyperoxidation
(Fig. 1f). The strong Prx-SO2/3H band represents hyperox-
idized PrxII (Papadia et al. 2008), although a higher
exposure of the blot reveals hyperoxidation of the upper
band identiﬁed as Prx III (Papadia et al. 2008) which also
appears to be weaker in D3T-treated neurons (Fig. 1f).
Therefore, D3T pre-treatment renders neurons resistant to
oxidative stress and inhibits the appearance of hyperoxi-
dized Prx protein.
Sulfiredoxin expression is induced in glia and neurons by
activators of Nrf2
Because D3T-treated neurons displayed lower levels of Prx-
SO2/3H in response to H2O2 treatment (Fig. 1f), we studied
the transcriptional regulation of the two genes whose
products mediate reduction of Prx-SO2/3H: sulﬁredoxin
[Srxn1, (Rhee et al. 2007)] and sestrin2 [Sesn2 (Budanov
et al. 2004)]. We found that D3T induced transcription of
Srxn1, producing an increase at both the mRNA and protein
level in cortical neurons (Fig. 2a and b). In contrast, D3T did
not induce expression of Sesn2. Other Nrf2 activators (tBHQ
and sulforaphane) also promoted expression of Srxn1 but not
Fig. 1 Neuronal Nrf2 expression and the Nrf2 activator D3T protects
neurons against oxidative stress; D3T inhibits the formation of
inactivated, hyperoxidized peroxiredoxins following oxidative trauma.
(a) Upper: example of an e-GFP expressing cell immuno-positive for
NeuN. Lower: example of an e-GFP expressing cell immuno-negative
for GFAP. Scale bar = 30 lm. (b) Effect of expressing Nrf2 in cortical
neurons on H2O2-induced neuronal death. The neurons were
transfected with control vector or pNrf2, plus an eGFP expression
vector to monitor cell fate (see methods). Twenty four hours post-
transfection neurons were treated where indicated with H2O2 (100 lM
here and throughout the study) and cell fate monitored after a further
24 h. For each vector/treatment, approx. One hundred and fifty cells
were studied across three independent experiments.*p < 0.05 Bon-
feronni two-tailed paired t-test. (c) Effect of expressing Nrf2 in cortical
neurons on survival of nearby cells in response to H2O2-treatment.
Survival/death of neurons within a 150 lm radius of Nrf2-expressing
neurons was analyzed by assessing nuclear morphology of DAPI
stained fixed cells. As can be seen in (d), healthy neurons have large
nuclei with diffuse DAPI staining. Apoptotic nuclei are characterised by
pyknotic brightly stained clumps of condensed chromatin. Survival/
death of over 1000 cells was scored across three independent
experiments. *p < 0.05 Bonferonni two-tailed paired t-test (n = 3). (d)
Example pictures relating to the data shown in (b). Arrows point to the
transfected cells identified by co-expression of eGFP. Pictures before
and after H2O2 treatment are taken of the cell, and DAPI stained
images are also taken post-treatment. Scale bar = 30 lm (e) Cell
death because of 24 h H2O2 insult in the face of the indicated
treatments. (Lower) Examples pictures, scale bar = 25 lm. *p < 0.05
Bonferonni two-tailed paired t-test (compared to control H2O2 treated,
n = 4), mean ± SEM shown in this and all cases. (f) Western analysis
of Prx hyperoxidation using an anti-PrxSO2/3H specific antibody. Two
exposures are shown for optimal visibility of hyperoxidized Prx II and
Prx III respectively. Analysis of PrxSO2/3H levels is restricted to Prx II,
and is normalized to total Prx II expression. *p < 0.05 Bonferonni
two-tailed paired t-test (compared to control, H2O2-treated neurons,
n = 7).
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Sesn2 (Fig. 2a) strongly suggesting that Srxn1 is a Nrf2
target gene.
Since our cortical neuronal cultures contain 5–10% of glial
cells (Papadia et al. 2008) we wanted to know whether these
Nrf2 activators are promoting Srxn1 expression in neurons or
glia or both. We performed experiments comparing Srxn1
expression in pure glial cultures (> 98% GFAP-positive,
Fig. 2c) with that of our mixed cultures. Expression of Srxn1
within the neuronal cultures was not signiﬁcantly different to
that in glial cultures (normalizing to 18S rRNA levels, data not
shown). Therefore, in our neuronal cultures, the 5–10%of glial
cells by number represent a similar percentage of total Srxn1
mRNA. We found that D3T induced Srxn1 expression in pure
glial cultures at 4 h by around 6-fold (Fig. 2d), similar to the
level of induction of Hmox1 (a known Nrf2-regulated gene,
Fig. 2d). Assuming that the glial cells within the neuronal
cultures respond similarly, induction of Srxn1 in glial cells
alone cannot account for the 3.5-fold induction of Srxn1 by
D3T in the neuronal cultures. The 3.5-fold induction observed
can only be explained if D3T can induce Srxn1 in the neurons
as well as glial cells (possibly by around 3.2-fold).
Nrf2 directly regulates Srxn1 expression via a cis-acting
ARE
We next investigated whether Srxn1 is directly regulated by
Nrf2. Nrf2 acts by binding the cis-acting antioxidant response
element (ARE) in the promoters of target genes.Analysis of the
rat Srxn1 promoter revealed a sequence at –188 relative to the
transcription start site (TCACCCTGAGTCAGCG) which
resembled an ARE (Nioi et al. 2003), and was conserved in
the gene from various mammalian species (Fig. 3a). To test
whether this putative element is functional we created a
luciferase reporter of the Srxn1 promoter containing 585 nt of
5¢ promoter sequence (from –577 to +8). We then analysed the
effect of Nrf2 expression on activity of this reporter. We ﬁrst
used primary cortical neuronal cultures and found that driven
Nrf2 expression induced Srxn1-Luc reporter gene activity
(Fig. 3b). Furthermore, mutation of the core of the putative
ARE (to TCACCCTGGGCCCGCG, Srxn1(mut)-Luc) abol-
ished Nrf2-responsiveness (Fig. 3b). The capacity of Nrf2 to
induce Srxn1-Luc was similar to its capacity to induce an
artiﬁcial ARE-Luc reporter (Numazawa et al. 2003), gener-
ated by placing AREs from the Heme oxygenase-1 (Hmox1)
promoter upstream of the luciferase open reading frame
(Fig. 3c). This indicates that the Srxn1 putative ARE is a bona
ﬁde Nrf2-responsive element, and is similarly responsive to
Nrf2 as the Hmox1 AREs.
To test whether endogenous Srxn1 was also induced by
Nrf2, we over-expressed Nrf2 in neurons and performed
immunocytochemistry with an appropriate antibody. The
transfected neurons exhibited elevated levels of Srxn1
(Fig. 3d), conﬁrming that the endogenous gene is also
Nrf2-responsive. We next investigated whether the Srxn1
ARE was responsive to Nrf2 in other cell types, since Srxn1
expression is induced in glial cells by D3T as well as neurons
(Fig. 2). Nrf2 induced Srxn1 promoter activity in glial cells
(Fig. 3e) to a similar degree as it activated ARE-Luc
(Fig. 3f). We also observed Nrf2-responsiveness of the
Srxn1 ARE in HEK293 cells (Fig. 3g) conﬁrming the ARE’s
functionality in several cell types.
Nrf2 controls the basal expression of Srxn1 in glia but not
in neurons
To determine whether Nrf2 controls basal levels of Srxn1
expression in neurons and glia, we ﬁrst looked at the relative
basal activity of Srxn1-Luc and Srxn1(mut)-Luc in both
neurons and glia (Fig. 3b and f). Mutation of the ARE
Fig. 2 Chemopreventive inducers of endogenous Nrf2 induce Srxn1
expression in neurons and glia. (a) Neuronal cultures were treated with
D3T (25 lM), tBHQ (10 lM, Aldrich, Milwaukee, WI, USA) or sulfor-
aphane (5 lM, Merck Biosciences, Darmstadt, Germany) for 4 h
followed by RNA extraction and q-RT-PCR analysis of Srxn1 and
Sesn2 (normalized to GAPDH). *p < 0.05 (Bonferonni two-tailed t-test,
n = 3–5). (b) Western analysis of Srxn1 protein expression in extracts
taken from neuronal cultures treated for 24 h with D3T (25 lM).
*p < 0.05 (n = 6). (c) GFAP immunofluorescence of glial cultures.
(d) Glial cultures were treated with D3T (25 lM) for 4 h followed by
RNA extraction and q-RT-PCR analysis of Srxn1, Sesn2 and Hmox1
(normalized to GAPDH, *p < 0.05, two-tailed t-test in this and sub-
sequent experiments unless otherwise stated, n = 6).
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sequence within the construct had only a modest effect on
basal Srxn1 promoter activity in neurons (Fig. 3b) but
reduced basal promoter activity in glia by around 80%
(Fig. 3f), suggesting that glial Srxn1 mRNA levels rely on
Nrf2 activity. However, the Srxn1 ARE contains an embed-
ded AP-1 like sequence, so basal activity could be because of
AP-1 activity rather than Nrf2. To investigate this further, we
examined the effect of suppressing basal Nrf2 activity by
expressing Keap1, an endogenous repressor of Nrf2 which
targets Nrf2 for proteosomal degradation (McMahon et al.
2003; Zhang 2006). Keap1 over-expression suppressed basal
ARE-Luc expression in glial cells but not in neurons (Fig. 4a
and b). In both glia and neurons, Keap1 impaired ARE
activity induced by Nrf2 expression (Fig. 4a and b),
conﬁrming that Keap1 was functioning properly in neurons.
These experiments indicate that basal Nrf2 activity is
relatively low in neurons compared to glia consistent with
other studies (Shih et al. 2003). Analysis of Srxn1 reporter
activity revealed that Keap1 effectively suppressed basal
glial Srxn1 expression but failed to affect neuronal basal
Srxn1 reporter activity (Fig. 4c and d), consistent with
normal constitutive levels of Nrf2 activity in neurons being
low. This indicates that factors other than Nrf2 are respon-
sible for maintaining basal levels of sulﬁredoxin in neurons.
Fig. 3 The Srxn1 promoter contains an ARE which is induced by Nrf2
expression in cortical neurons, as is the endogenous gene. (a)
Schematic showing the putative ARE within mammalian Srxn1
promoters. (b) Effect of Nrf2 expression on wild-type and mutant
Srxn1-Luc reporters (normalized to Renilla control-see methods).
Neurons were transfected with Srxn1 reporter plus pcDNA3.1-Nrf2 or
pGlobin control plasmid. NB. In this and all experiments ‘con’ denotes
pGlobin control vector. *p < 0.05 (2-tailed paired t-test, n = 3–5). (c)
Effect of Nrf2 expression on ARE-Luc activity. *p < 0.05 (n = 5). (d)
Effect of transfecting pEF-Nrf2 on endogenous Srxn1 expression.
Neurons were transfected with the indicated vectors and after 24 h
subjected to immunocytochemical analysis of sulfiredoxin expression.
Immunofluorescence performed as described (McKenzie et al. 2006).
Scale bar = 40 lm. (e) Effect of Nrf2 expression on WT and mutant
Srxn1-Luc reporters in glial cells *p < 0.05 (n = 7). (f) Effect of Nrf2
expression on ARE-Luc activity in glial cells. *p < 0.05 (n = 4).
(g) Effect of Nrf2 expression on WT and mutant Srxn1-Luc reporters in
HEK293cells. *p < 0.05 (n = 3).
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Activity-dependent induction of Srxn1 is largely
independent of Nrf2
We reported previously that synaptic activity strongly
induces Srxn1 via the two AP-1 sites at –188 and –239
(Papadia et al. 2008). The proximal AP-1 site identiﬁed in
this earlier study is in fact contained within the core of the
ARE identiﬁed here. This raises the possibility that some of
the activity-dependent induction of Srxn1 is actually due to
Nrf2 activation. We used an established method of network
disinhibition to enhance synaptic activity, applying the
GABAA receptor antagonist bicuculline to induce bursting,
and the K+ channel antagonist 4-aminopyridine [which
enhances burst frequency, hereafter BiC/4-AP (Hardingham
et al. 2001)]. We analyzed the effect of Keap1 on activity-
dependent induction of the Srxn1 promoter and found a small
but signiﬁcant reduction after 8 h stimulation (Fig. 5a), but
not at 24 h stimulation [the time-point used in our previous
study (Papadia et al. 2008)]. By comparison we found that
induction of a reporter of Sesn2, which is also induced by
synaptic activity, was not inhibited by Keap1 at either time-
point (Fig. 5a). To test this further, we investigated the
degree to which activity-dependent induction of the com-
posite ARE/AP-1 site is dependent on AP-1. We utilized
expression of TAM67, a dominant negative form of c-jun
which interferes with AP-1 mediated gene expression.
Activity-dependent induction of a reporter containing ﬁve
tandem AP-1 sites is inhibited by 65% by TAM67 (Fig. 5b).
Induction of the mutant Srxn1 reporter dependent on the
distal AP-1 site (i.e. with the composite ARE/AP-1 site
mutated) was inhibited by 55% (Fig. 5b), similar to inhibi-
tion of a pure AP-1 reporter. In contrast, induction of the
mutant Srxn1 reporter dependent on the composite ARE/
AP-1 site (i.e. with the distal AP-1 site mutated) was
inhibited by only 30% (Fig. 5b). Thus, our data indicate that
at early time-points the activity-dependent induction of the
composite ARE/AP-1 site is partly dependent on AP-1, and
is also partly dependent on Nrf2.
Fig. 4 Basal levels of Srxn1 promoter activity are sensitive to Keap1
expression in glia but not neurons. (a,b) Effect of Keap1 expression on
basal and Nrf2-driven ARE-Luc reporter activity in neurons (a) and glia
(b). Cells were transfected with ARE-Luc plus pcDNA3.1-Nrf2 (or
pGlobin), plus pcDNA3.1-Keap1 (or pGlobin). *p < 0.05 (n = 4–6).
(c,d) Effect of Keap1 expression on basal Srxn1-Luc reporter activity in
neurons (c) and glia (d). *p < 0.05 (n = 4).
Fig. 5 Activity-dependent induction of Srxn1 via the ARE/AP-1 site is
primarily mediated by AP-1. (a) Effect of Keap1 expression on activity-
dependent induction of reporters of Srxn1 and Sesn2. Neurons were
transfected with the reporter plus TK-driven Renilla control vector.
Twenty four hours post-transfection, bursts of action potential firing
were induced by treatment of neurons with 50 lM bicuculline, and
burst frequency was enhanced by addition of 250 lM 4-amino pyridine
(Hardingham et al. 2001). Reporter activity was assayed after the
indicated time periods. *p < 0.05 Bonferonni two-tailed paired t-test
(compared to control, BiC/4-AP-stimulated level, n = 6). (b) Effect of
an interfering mutant of AP-1 (TAM67) on activity-dependent induction
of the putative ARE/AP-1 composite site, compared to an upstream
AP-1 site. Neurons were transfected with the indicated reporter con-
structs, plus pTK-RL and either control vector or expression vector for
TAM67. Twenty four hours post-transfection neurons were stimulated
with BiC/4-AP overnight prior to assay of reporter activity (n = 5).
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Discussion
This study provides evidence that activation of the Nrf2
pathway speciﬁcally within neurons can antagonize H2O2-
stimulated apoptosis. We also show that activation of this
pathway can prevent hyperoxidation of peroxiredoxins that
occurs in neurons upon exposure to an oxidative insult. Also
we have found that expression of sulﬁredoxin, an enzyme
that reduces hyperoxidized peroxiredoxins, is regulated by
Nrf2 in neurons and other cell types. Thus, expression of
sulﬁredoxin may contribute to the antioxidative effects of
chemopreventive agents that activate Nrf2.
Reactivation of peroxiredoxins by sulfiredoxin
Peroxiredoxins are a family of thiol-based antioxidants that
protect against damage caused by oxidative stressors. PrxII
protects cortical neurons against Ab toxicity (Yao et al.
2007) and oxygen-glucose deprivation (Boulos et al. 2007).
Interfering with PrxII expression renders neuroblastoma
cells vulnerable to oxidative stress (Sanchez-Font et al.
2003), and renders cortical neurons vulnerable to MPP+
(Qu et al. 2007). PrxIII protects hippocampal neurons
against excitotoxicity (Hattori et al. 2003). Thus, molecular
events that render Prxs inactive in vivo in pathological
scenarios may contribute to disease progression. We have
previously observed Prx-inactivating Prx-SO2/3H formation
following cerebral ischemia in vivo (Papadia et al. 2008). It
remains to be seen whether Prx hyperoxidation occurs in
more chronic neurodegenerative diseases associated with
oxidative stress.
Sulﬁredoxin was initially characterized in yeast (Biteau
et al. 2003) and then in mammalian cells (Rhee et al. 2007).
It acts by catalysing the ATP-dependent formation of a
sulﬁnic acid phosphoric ester on Prx (Rhee et al. 2007)
which is then reduced by thiol equivalents such as thiore-
doxin. Interfering with Srxn1 expression impairs the ability
of cells to reduce hyperoxidized Prxs, while over-expression
of Srxn1 enhances it (Chang et al. 2004; Woo et al. 2005).
Our ﬁnding that Srxn1 expression can be induced by small
thiol-active molecules that activate Nrf2 suggests that
exposure to such inducers may increase the level of
peroxides that a cell can tolerate before Prx is inactivated
by hyperoxidation. Given the antioxidant and cytoprotective
effects of Prxs, induction of sulﬁredoxin expression may be a
signiﬁcant contributor to the net effects of Nrf2 activation. It
will be of considerable interest to see whether Nrf2
activators are able to reduce Prx-SO2/3H formation following
cerebral ischemia in vivo. This seems possible, since pre-
administration of the Nrf2 activators tBHQ and sulforaphane
can protect the brain from cerebral ischemia in vivo (Shih
et al. 2005; Zhao et al. 2006). According to our observa-
tions, D3T is a superior neuroprotectant, so it will be of
interest to know whether it is an efﬁcient protector against
ischemic injury.
Nrf2 is a therapeutic target for many disorders
Up-regulation of Nrf2 activity in Drosphila increases lifespan
and resistance to oxidative stress (Sykiotis and Bohmann
2008). In mammals, gene expression programs induced by
Nrf2 can protect many different organs against a variety of
traumas. For example, Nrf2 protects lung against hyperoxic
injury (Cho et al. 2002), and the liver against paracetamol-
induced hepatotoxicity (Enomoto et al. 2001). Nrf2 is the
primary molecular target of cancer chemopreventive block-
ing agents (Giudice and Montella 2006) which in general act
by preventing carcinogens from forming adducts with DNA
that lead to mutations. The boosting of intrinsic antioxidant
defences of the cell by activation of Nrf2 is believed to be an
important mediator of these protective effects, as is the co-
ordinated induction of detoxiﬁcation enzymes such as
glutathione S-transferases and NAD(P)H:quinone oxidore-
ductase 1. The program of gene expression induced by Nrf2
is well-placed to combat the actions and the production of a
variety of free radicals. For example, the Nrf2 target gene
Ferritin sequesters Fe(II) and can thus restrict hydroxyl
radical-generating Fenton chemistry. Also, the Nrf2 target
gene Hmox1 degrades the pro-oxidant heme molecule,
generating bilirubin as a breakdown product. Bilirubin can
react directly with, and neutralize, superoxide, hydroxyl and
peroxynitrite radicals (Stocker 2004). The actions of these,
and other, gene products, in concert with those involved in
the thiol-based antioxidant systems result in a powerful and
general up-regulation of antioxidant defenses (Lee et al.
2005).
In the CNS, Nrf2 has been suggested to be a therapeutic
target in excitotoxic disorders such as stroke and seizure, as
well as neurodegenerative diseases (Lee et al. 2005; Shih
et al. 2005). While Nrf2 over-expressing glial cells strongly
protect surrounding untransfected neurons (Shih et al. 2003;
Kraft et al. 2004; Jakel et al. 2007), it was not clear whether
Nrf2 can act solely in neurons to confer neuroprotection
against oxidative insults. The electrophile NEPP11 induces
Nrf2 preferentially but not exclusively in neurons (Satoh
et al. 2006) and protects against models of NMDA receptor-
dependent excitotoxicity. This suggested that Nrf2 can act in
neurons, but contributions from glial cells could not be ruled
out. Our results show that Nrf2 is strongly neuroprotective in
neurons and that neuroprotection need not rely on glial Nrf2
expression.
The neuroprotective effect of Nrf2 places the many known
activators of Nrf2 as potential lead compounds. We have
found that the ability of different agonists of Nrf2 to induce
Srxn1 and Hmox1 expression in neurons is not matched by
their neuroprotective effects. In our hands, D3T is a
far superior neuroprotectant than sulforaphane or tBHQ
(G. E. Hardingham, unpublished data). Oltipraz, a struc-
tural relative of D3T, has also been found to be protective
(G. E. Hardingham, unpublished data). We hypothesize that
in our particular system, tBHQ and sulforaphane induce Nrf2
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target genes only at a dose that may exert signiﬁcant toxicity,
hence their relative lack of efﬁcacy. This toxicity is likely
because of unspeciﬁed off-target effects. Thus, while activa-
tors of Nrf2 remain attractive candidates for acute and
chronic neurodegenerative disorders associated with oxida-
tive stress, the therapeutic window of each molecule is of
paramount importance with regard to its direct efﬁcacy, even
before pharmacodynamic and pharmacokinetic factors are
considered.
The AP-1/ARE composite site in the Srxn1 promoter can
integrate multiple signals
Our observations here and elsewhere (Papadia et al. 2008)
identify Srxn1 as a gene regulated by both AP-1 (via two
phorbol 12-O-tetradecanoate 13-acetate-response element
sites) and Nrf2 (one ARE site). Moreover, the proximal
AP-1 site is contained within the ARE sequence. Several
AREs such as those in the promoters of human NQO1 and
HMOX1 contain AP-1 like sequences and can respond to AP-
1-activating stimuli, as well as Nrf2 (Nguyen et al. 2004).
The composite ARE/AP-1 site on the Srxn1 promoter
enables it to respond both to small molecule Nrf2 inducers
such as D3T and tBHQ, as well as to synaptic activity
(mainly via AP-1). Induction of Srxn1 by synaptic activity
contributes to the protection of cortical neurons by synaptic
activity in the face of an oxidative insult (Papadia et al.
2008). It is an intriguing possibility that the protective effects
of synaptic activity and Nrf2 inducers may have a partially
overlapping mechanism: induction of certain genes contai-
ning ARE/AP-1 composite sites.
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